Ensign Peak Advisors
CDAK

Ensign Peak Advisors’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Ensign Peak Advisors’s Portfolio CDAK Stock Details CDAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-252,782
Closed -$44.1K – 1794
2023
Q1 		$44.1K Hold
252,782
– – ﹤0.01% 1765
2022
Q4 		$101K Sell
252,782
-267,539
-51% -$176K ﹤0.01% 1766
2022
Q3 		$407K Sell
520,321
-88,784
-15% -$186K ﹤0.01% 1564
2022
Q2 		$1.75M Sell
609,105
-59,383
-9% -$209K ﹤0.01% 855
2022
Q1 		$4.19M Buy
668,488
+159,051
+31% +$998K 0.01% 641
2021
Q4 		$5.67M Buy
509,437
+35,430
+7% +$491K 0.01% 632
2021
Q3 		$7.74M Sell
474,007
-176,505
-27% -$3.16M 0.02% 498
2021
Q2 		$12.1M Hold
650,512
– – 0.02% 391
2021
Q1 		$9.81M Sell
650,512
-169,315
-21% -$3.68M 0.02% 423
2020
Q4 		$26.5M Buy
+819,827
New +$10.8M 0.06% 267

Ensign Peak Advisors's CDAK Position: Q2 2023 in Review

Ensign Peak Advisors sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q2 2023, closing a stake of 252,782 shares — an estimated $44.1K sold.

Ensign Peak Advisors first reported a position in CDAK in Q4 2020 and held it in 10 quarters. The position peaked at $26.5M in Q4 2020. 1 fund tracked by Wall St. Rank holds CDAK as of Q2 2023.

  • Ensign Peak Advisors reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Ensign Peak Advisors sold 252,782 Codiak BioSciences, Inc. Common Stock shares in Q2 2023, an estimated $44.1K.
  • Ensign Peak Advisors first reported a position in Codiak BioSciences, Inc. Common Stock in Q4 2020 and held it in 10 quarters.
  • Ensign Peak Advisors's Codiak BioSciences, Inc. Common Stock position peaked at $26.5M in Q4 2020.
  • 1 fund tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q2 2023.

Based on Ensign Peak Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.